These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 33755878)
1. A review on inositol's potential in cyclic disturbances of adipose-endocrinology-associated polycystic ovary syndrome. Almalki WH Mol Cell Biochem; 2021 Aug; 476(8):2943-2949. PubMed ID: 33755878 [TBL] [Abstract][Full Text] [Related]
2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1. Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ; Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855 [TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Sanchez-Garrido MA; Tena-Sempere M Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180 [TBL] [Abstract][Full Text] [Related]
4. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633 [TBL] [Abstract][Full Text] [Related]
5. Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource. Azziz R; Kintziger K; Li R; Laven J; Morin-Papunen L; Merkin SS; Teede H; Yildiz BO Hum Reprod; 2019 Nov; 34(11):2254-2265. PubMed ID: 31751476 [TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824 [TBL] [Abstract][Full Text] [Related]
7. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model. Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534 [TBL] [Abstract][Full Text] [Related]
9. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Unfer V; Porcaro G Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153 [TBL] [Abstract][Full Text] [Related]
10. Is foetal hyperexposure to androgens a cause of PCOS? Filippou P; Homburg R Hum Reprod Update; 2017 Jul; 23(4):421-432. PubMed ID: 28531286 [TBL] [Abstract][Full Text] [Related]
11. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Laven JS; Imani B; Eijkemans MJ; Fauser BC Obstet Gynecol Surv; 2002 Nov; 57(11):755-67. PubMed ID: 12447098 [TBL] [Abstract][Full Text] [Related]
12. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. Legro RS; Chiu P; Kunselman AR; Bentley CM; Dodson WC; Dunaif A J Clin Endocrinol Metab; 2005 May; 90(5):2571-9. PubMed ID: 15713728 [TBL] [Abstract][Full Text] [Related]
13. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Holte J Baillieres Clin Endocrinol Metab; 1996 Apr; 10(2):221-47. PubMed ID: 8773746 [TBL] [Abstract][Full Text] [Related]
14. Adipose tissue dysfunction in polycystic ovary syndrome. Villa J; Pratley RE Curr Diab Rep; 2011 Jun; 11(3):179-84. PubMed ID: 21424395 [TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities. Elkind-Hirsch KE Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059 [TBL] [Abstract][Full Text] [Related]